Tanic Nikola, Brkic Gordana, Dimitrijevic Bogomir, Dedovic-Tanic Nasta, Gefen Nir, Benharroch Daniel, Gopas Jacob
Department of Neurobiology and Immunology, Institute of Biological Research "Sinica Stankovic", Belgrade, Israel.
Anticancer Res. 2006 May-Jun;26(3A):2137-42.
Malignant melanoma resistance to chemotherapy remains a major limitation to treatment. Our aim was to identify genes associated with drug resistance, in order to better understand the molecular events underlying the drug-resistant phenotype.
A human melanoma cell line and its drug-resistant variants obtained by selection with MNNG or 6-thioguanine were used. Alterations in gene expression were characterized by differential display reverse transcription-polymerase chain reaction (DDRT-PCR). Prominent mRNA fragments present in selected variants and not in the parental cells were identified and characterized by cloning and sequencing. Differential expression was confirmed by real-time RT-PCR.
Three functionally distinct transcriptional products were demonstrated: the chaperonin subunit TCP 1-zeta-6A (CCT6A), the hyaluronan receptor CD44 and LPPR-2, the lipid phosphate phosphatase-related protein type-2.
Genes with altered expression were identified in drug-resistant variants. The identified molecules may provide new insights into the molecular basis for melanoma resistance to chemotherapy.
恶性黑色素瘤对化疗的耐药性仍然是治疗的主要限制因素。我们的目的是鉴定与耐药性相关的基因,以便更好地理解耐药表型背后的分子事件。
使用通过用MNNG或6-硫鸟嘌呤筛选获得的人黑色素瘤细胞系及其耐药变体。通过差异显示逆转录-聚合酶链反应(DDRT-PCR)来表征基因表达的改变。通过克隆和测序鉴定并表征所选变体中存在而亲代细胞中不存在的显著mRNA片段。通过实时RT-PCR确认差异表达。
证明了三种功能不同的转录产物:伴侣蛋白亚基TCP 1-ζ-6A(CCT6A)、透明质酸受体CD44和LPPR-2,即2型脂质磷酸磷酸酶相关蛋白。
在耐药变体中鉴定出表达改变的基因。所鉴定的分子可能为黑色素瘤对化疗耐药的分子基础提供新的见解。